Cochlear Stock Rating Reaffirmed by Credit Suisse (COH)
Cochlear (ASX:COH)‘s stock had its “underperform” rating reaffirmed by analysts at Credit Suisse in a research report issued to clients and investors on Tuesday, Stock Ratings Network reports.
Cochlear (ASX:COH) traded up 0.86% during mid-day trading on Tuesday, hitting A$58.350. 8,241 shares of the company’s stock traded hands. Cochlear has a 52 week low of A$52.710 and a 52 week high of A$82.870. The stock has a 50-day moving average of A$59.14 and a 200-day moving average of A$63.40. The company has a market cap of A$3.321 billion and a P/E ratio of 24.89.
Several other analysts have also recently commented on the stock. Analysts at CIMB reiterated an “underperform” rating on shares of Cochlear (ASX:COH) in a research note to investors on Sunday, August 25th.
Three research analysts have rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of A$70.54 ($64.72).
Cochlear Limited (ASX:COH) is an Australia-based company, which operates in the implantable hearing device industry.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.